Side-by-side comparison of AI visibility scores, market position, and capabilities
Vizgen is a Cambridge MA life sciences company commercializing MERSCOPE, a spatial genomics platform based on MERFISH technology licensed from Harvard; enables single-cell, subcellular-resolution RNA imaging in intact tissue;
Vizgen is a life sciences company founded in 2019 and headquartered in Cambridge, Massachusetts, that has commercialized the MERSCOPE platform — a spatial genomics instrument based on MERFISH (Multiplexed Error-Robust Fluorescence In Situ Hybridization) technology originally developed in the lab of Xiaowei Zhuang at Harvard University. MERSCOPE enables researchers to simultaneously measure the expression of hundreds to thousands of genes in individual cells while preserving the spatial location of those cells within intact tissue samples. This combination of single-cell resolution and spatial context is a significant advance over traditional bulk RNA sequencing (which loses spatial information) and earlier single-cell sequencing methods (which require tissue dissociation that destroys spatial architecture).
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.